ãã®èšäºã§æ±ãå 容
èŽèŠå»çã«ãããèšåºè©Šéšã®é²ã¿æ¹ãç ç©¶ã®çš®é¡ãåå è ä¿è·ãšã€ã³ãã©ãŒã ãã³ã³ã»ã³ããä¿¡é Œã§ãã詊éšã®æ¢ãæ¹ãåå æã«äžè¬çã«å«ãŸããå 容ãèããããå©çãšãªã¹ã¯ããããŠç ç©¶åå ããèªèº«ã«é©ããŠãããã®å€ææ¹æ³ã«ã€ããŠèª¬æããŸãã
éèŠãªå®å šã¡ã¢
æ°æéããæ°æ¥ã®ãã¡ã«èµ·ããçªç¶ã®é£èŽãçåŽã ãã®æ¥ãªèŽããã®å€åããŸãã¯åŒ·ãããŸããããå Žåã¯ãç·æ¥ã®å¯Ÿå¿ãå¿ èŠãšèããŠãã ãããç ç©¶åå ã¯ç·æ¥è©äŸ¡ã®ä»£ããã«ã¯ãªããŸããã
ãç·æ¥æ: èŽåã»è³é³Žãã»ãã©ã³ã¹ã®å®å šã¬ã€ãããžé²ã
ãèšåºè©Šéšããšããèšèã«äžå®ãæããæ¹ã¯å°ãªããããŸããã人ã¯ãã°ãã°ããªã¹ã¯ããŸã ååããããªãå®éšçãªæ²»çãæ³åããèªåãã±ã¢ãåãã人ã§ã¯ãªãâå®éšå°âã«ãªãããã«æããŠããŸããŸããé£èŽãè³é³Žãã«åãåã£ãŠãããšããç ç©¶åå ãèããããšã¯ããã§ã«é£ããæ²»çã®å€æã«ããã«éãã®ããããããšããããŸãã
ããããå€ãã£ãŠããããšããããŸããç±³åœã§ã¯ã人ã察象ãšããã»ãšãã©ã®èšåºç ç©¶ããã€ã³ãã©ãŒã ãã³ã³ã»ã³ããšå«ç審æ»ã«é¢ããæ£åŒãªã«ãŒã«ã®ããšã§è¡ãããŠããŸããããããä¿è·ã¯çŸå®ã«ååšããŸããããã¹ãŠã®ç ç©¶ã§ãŸã£ããåããšããããã§ã¯ãããŸãããç ç©¶åå ã¯ãã¢ã«ã¢ããã«ãªããããšã§ã¯ãããŸãããå®å šæ§ãšå©çã«ã€ããŠçããåºãããã®ãæŽçãããæ¹æ³ã§ãããããŠã質åããæš©å©ãšããã€ã§ãç ç©¶ãé¢ããæš©å©ããããŸããèŽèŠå»çã§ã¯ãé£èŽã®ç¹å®ã®éºäŒçåå ã察象ãšããå è³ã®éºäŒåæ²»çãå«ãåææ®µéã®ç ç©¶ã§ãäžéšã®åå è ã«æ¹åãå ±åãããŠããŸããããããã®æ¹æ³ã¯ãŸã å®éšçã§ãããé·æçãªå®å šæ§ãå¹æã®æç¶æ§ã«ã€ããŠã¯åŒãç¶ãç ç©¶ãå¿ èŠã§ãã
èŽèŠå»çã«ãããèšåºè©Šéšã®é²ã¿æ¹
èšåºè©Šéšã§ã¯ãæ°ããæ²»çãæ©åšãè¬ããŸãã¯ã¢ãããŒããåºã䜿ãããåã«è©äŸ¡ãããŸããèŽèŠå»çã®ç ç©¶ã§ã¯ãããšãã°æ¬¡ã®ãããªãã®ãæ€èšãããŸãã
- èŽèŠãã¯ãããžãŒ: æ°æ©èœãä¿¡å·åŠçãæ¥ç¶æ§ãã¢ããªããã£ããã£ã³ã°æŠç¥
- 人工å è³ã®ã¢ãããŒã: 黿¥µãã¶ã€ã³ãããã°ã©ãã³ã°æŠç¥ãèŽåæž©åæè¡
- è¬ç©: è³é³Žããçªçºæ§é£èŽããã®å埩ããŸãã¯ç¹å®ã®é£èŽäºé²ãç®çãšããæ²»ç
- éºäŒåã«åºã¥ãæ¹æ³: é£èŽã®ç¹å®ã®éºäŒçåå ãæšçãšããæ²»çïŒåææ®µéã§éåžžã«éå®çïŒ
- ãªãããªããŒã·ã§ã³: èŽèŠãã¬ãŒãã³ã°ãè³é³Žã管çãã³ãã¥ãã±ãŒã·ã§ã³æŠç¥
èšåºè©Šéšã®æ®µéïŒæŠèŠïŒ
第1çžïŒå®å šæ§ïŒ: éåžžã¯å°èŠæš¡ã§ãå®å šæ§ãçšéïŒè¬ã®å ŽåïŒãå¯äœçšã«éç¹ã眮ããŸãã
第2çžïŒåæã®æå¹æ§ïŒ: 广ã®å åãããããèŠãªãããå®å šæ§ãæé©ãªäœ¿ãæ¹ãåŒãç¶ã調ã¹ãŸãã
第3çžïŒç¢ºèªïŒ: ããå€§èŠæš¡ãªç ç©¶ã§ãæšæºæ²»çãå¥ã®å¯Ÿç §çŸ€ãšæ¯èŒãããããšãå€ããããŸãã該åœããå ŽåãçµæãFDAã®æ¿èªãèš±å¯ã®æ ¹æ ã«ãªãããšããããŸãã
第4çžïŒåžè²©åŸïŒ: æ¿èªãŸãã¯èš±å¯ã®åŸãããå®éã®äœ¿çšç°å¢ãã§ãŸããªå¯äœçšãé·æçãªæ§èœã確èªããããã®ç£èŠãç¶ããŸãã
çµã¿èŸŒãŸããŠããä¿è·ã®ä»çµã¿ïŒç¢ºèªãããç¹ïŒ
人ã察象ãšããå€ãã®ç ç©¶ã¯ãæœèšå 審æ»å§å¡äŒïŒIRBïŒã®å¯©æ»ãåããŸããIRBã¯ããªã¹ã¯ã劥åœãã©ãããåæååŸã®éçšãé©åãã©ãããè©äŸ¡ããŸãã詊éšã«ã¯å®å šæ§ã«é¢ããå ±å矩åãããããªã¹ã¯ãé«ãç ç©¶ã§ã¯ãããã«ç¬ç«ããå®å šæ§ç£ç£ãå ããããšããããŸãã
çŸåšã®èŽèŠå»çç ç©¶ã®çš®é¡
éºäŒåæ²»çç ç©¶ïŒåææ®µéã§éåžžã«éå®çïŒ
å è³ã®éºäŒåæ²»çã«é¢ããåææ®µéã®ç ç©¶ã§ã¯ãDFNB9/OTOFé¢é£ã®èŽèŠãã¥ãŒããããŒãªã©ãé£èŽã®ç¹å®ã®éºäŒçåå ãæã€å°æ°ã®åã©ãã§èŽåæ¹åãå ±åãããŠããŸãããããã®æ²»çã¯ãŸã å®éšçã§ããé·æçãªå®å šæ§ã广ãã©ã®ãããç¶ããã誰ããã£ãšãæ©æµãåãããããã«ã€ããŠã¯ãéèŠãªçåããŸã æ®ã£ãŠããŸãã
æ©åšã®æè¡é©æ°ã«é¢ããç ç©¶
è£èŽåšã人工å è³ã®ã¡ãŒã«ãŒã¯ãæ°æè¡ãåžå Žã«åºãåã«ç ç©¶ãè¡ãããšããããããŸããç ç©¶ã§ã¯æ¬¡ã®ãããªç¹ãè©äŸ¡ãããããšããããŸãã
- éšãããç°å¢ã§ã®äŒè©±çè§£
- æ¥åžžã®èããã®å Žé¢ã«ãããå¿«é©ããšé³è³ª
- æ¥ç¶æ§ãã¹ããªãŒãã³ã°æ§èœ
- æ°ãã人工å è³ããã°ã©ãã³ã°æŠç¥
äŒæ¥äž»å°ã®ã補åç ç©¶ã: 圹ç«ã€ããšããããŸãããèãã¹ãããšããããŸã
èŽèŠãã¯ãããžãŒäŒæ¥ããæ°ããè£èŽåšããã¡ãŒã ãŠã§ã¢ãã¢ããªããŸãã¯ãã£ããã£ã³ã°æ¹æ³ã®ç ç©¶ãžã®åå ãåŒã³ãããããšããããŸããæ£åŒãªèšåºç ç©¶ãããã°ã䜿ããããã補åãã£ãŒãããã¯ã®ããã®ç ç©¶ããããŸããã©ã¡ãã§ãã£ãŠããæ¬¡ã®ããšãé æ ®ãªãå°ããŠãã ããã
- IRBã®å¯©æ»ãåããŠããŸããïŒ åããŠãããªããã©ã®æ©é¢ã§ããïŒ
- 誰ããã®ç ç©¶ãåŸæŽããŠããŸããïŒïŒäŒæ¥ã倧åŠããŸãã¯ãã®äž¡æ¹ïŒ
- ã©ã®ãããªããŒã¿ãåéããããããããŒã±ãã£ã³ã°ã«äœ¿ãããå¯èœæ§ã¯ãããŸããïŒ
- èªåãè² æ ããè²»çšãšãç ç©¶ãè² æ ããè²»çšã¯äœã§ããïŒïŒæ©åšãéé¢ã亀éè²»ãå«ãïŒ
- éäžã§ããããã©ããªããŸããïŒ æ©åšã¯è¿åŽããŸããïŒ èšåºã±ã¢ã¯åãç¶ããããŸããïŒ
è¬ç©ãšäºé²ã«é¢ããç ç©¶
補è¬ç ç©¶ã§ã¯ãè³é³Žããç¹å®ã®å¹³è¡¡é害ãäžéšã®è¬å€é¢é£é£èŽã®äºé²ããŸãã¯æ¥ãªèŽåå€ååŸã®å埩æ¹åãç®çãšããè¬ãæ€èšãããããšããããŸããçµæã¯çŸæ£ã«ãã£ãŠããŸããŸã§ãå€ãã®æ¹æ³ããŸã ç ç©¶äžã§ãã
ä¿¡é Œã§ããç ç©¶ã®æ¢ãæ¹
ClinicalTrials.govïŒåœ¹ç«ã€åºçºç¹ïŒ
ClinicalTrials.govã¯ãå€ãã®ç ç©¶ãç»é²ãããŠããå€§èŠæš¡ãªããŒã¿ããŒã¹ã§ããç ç©¶ãèŠã€ããåå æ¡ä»¶ãèªã¿ãé£çµ¡å ã確èªããããã«äœ¿ããŸããç»é²æ å ±ã¯åºçºç¹ãšããŠæçšã§ãããããèªäœãæ¿èªã®èšŒã§ã¯ãããŸãããç ç©¶ããŒã ã宿œæœèšã®æ£åœæ§ããããŠIRB審æ»ãªã©ã®ç£ç£äœå¶ãå¿ ã確èªããŠãã ããã
广çãªæ¢ãæ¹
- å ·äœçãªçšèªã䜿ã: ãé£èŽããè³é³Žããã人工å è³ããèŽèŠãã¥ãŒããããŒããè³ç¡¬åçã
- åéç¶æ³ã§çµã蟌ãïŒäŸ: ãRecruitingãïŒã
- è¿ãã®ç ç©¶ãæ¢ãããã«å Žæã§çµã蟌ãã
- åå æ¡ä»¶ãããèªã¿ãçåãããã°ç ç©¶ããŒã ã«é£çµ¡ããã
倧åŠç é¢ãªã©ã®åŠè¡å»çæ©é¢
è³éŒ»åœåç§ãèŽèŠåŠããã°ã©ã ãæã€å€§åŠã§ã¯ãç ç©¶åå ã«é¢ããããŒãžãèšããŠããå ŽåããããŸããã¯ãªããã¯ã«çŽæ¥é»è©±ããŠãçŸåšé²è¡äžã®ç ç©¶ã«ã€ããŠå°ããããšãã§ããŸãã
äŒæ¥ãåŸæŽããç ç©¶
äŒæ¥ã¯æ°ããæ©åšããœãããŠã§ã¢ã«é¢ããç ç©¶ãåŸæŽããããšããããŸããããããç ç©¶ã§ã¯æ§é åããããã©ããŒã¢ãããåããããå ŽåããããŸããã誰ãç ç©¶ãåŸæŽããŠããã®ããã©ã®ããŒã¿ãåéãããã®ãããããŠéäžã§ãããå Žåã«ã©ããªãã®ããç¹ã«ç¢ºèªããããšãéèŠã§ãã
ç ç©¶è©æ¬ºã誀解ãæããç ç©¶ããé¿ããã«ã¯
å€ãã®ä¿¡é Œã§ãã詊éšã§ã¯ãå®éšçæ²»çãç ç©¶æ€æ»ã®ããã«åå è ãæ¯æãå¿ èŠã¯ãããŸãããã亀éè²»ãä»äºãäŒãæéãäžéšã®é垞蚺çè²»ãªã©ãè² æ ãçããããšã¯ãããŸããçµæãä¿èšŒããããåå ã匷ãè¿«ã£ãããé«é¡ãªåå è²»ãæ±ãããããç ç©¶ã«ã¯æ³šæããŠãã ãããClinicalTrials.govã®ç»é²ã¯è¯ãåºçºç¹ã§ãããããèªäœãæ¿èªã®èšŒã§ã¯ãããŸãããç ç©¶ããŒã ã宿œæœèšã®æ£åœæ§ãIRB審æ»ã®æç¡ã確èªããŠãã ããã
åå æã«äžè¬çã«å«ãŸããããš
æéãšãã©ããŒã¢ãã
ç ç©¶åå ã«ã¯ãéåžžã®èšºçãããå€ãã®æéãå¿ èŠã«ãªãããšããããŸããç ç©¶ã«ãã£ãŠã¯ãã¹ã¯ãªãŒãã³ã°å蚺ãè¿œå æ€æ»ãè€æ°åã®ãã©ããŒã¢ããåèšºãæ°ãæããæã«ã¯æ°å¹Žã«ããã質å祚ãžã®åçãå«ãŸããŸãã
ã€ã³ãã©ãŒã ãã³ã³ã»ã³ãïŒçœ²åã ãã§ã¯ãããŸããïŒ
ã€ã³ãã©ãŒã ãã³ã³ã»ã³ãã¯ãç¶ç¶çãªå¯Ÿè©±ã®ããã«æããããã¹ããã®ã§ããç ç©¶ã®ç®çãæé ãæ¢ç¥ã®ãªã¹ã¯ãæåŸ ãããå©çãä»£æ¿æ¡ããã©ã€ãã·ãŒä¿è·ããããŠéäžã§ãããæš©å©ã«ã€ããŠãæç¢ºãªèª¬æãåããå¿ èŠããããŸãã
ããªãã«ã§ããããš: å¿ èŠãªã ã質åãããæ±ºãããŸã§æéããšããå¿ èŠã§ããã°æ®æ®µã®å»çè ãå®¶æã«ååžããŠãããã
èããããå©çãšãªã¹ã¯
èããããå©ç
- ãŸã åºãå©çšã§ããªãéžæè¢ã«ã¢ã¯ã»ã¹ã§ããããšããã
- ãã®ç æ ã«è©³ããç ç©¶ããŒã ã«ããäœç³»çãªçµé芳å¯
- ããããæ ¹æ ã¥ãããéããŠå°æ¥ã®æ£è ã«åœ¹ç«ã€ããš
èãããããªã¹ã¯ãšéç
- ãŸã ããã£ãŠããªãå¯äœçšïŒç¹ã«åææ®µéã®ç ç©¶ïŒ
- å©çãããä¿èšŒã¯ãªã
- å¯Ÿç §çŸ€ã¯æšæºæ²»çãŸãã¯å¥ã®æ¯èŒæ²»çãåããå ŽåããããŸãããã©ã»ãã®äœ¿çšã¯ç ç¶ãšå«çç倿ã«ãããŸã
- æéãšè² æ ïŒç§»åã远å å蚺ã質å祚ïŒ
- ç ç©¶çµäºåŸã®å©çšå¯èœæ§ãéãããããšããã
ç ç©¶åå ãèªåã«åã£ãŠããã倿ããã«ã¯
ç ç©¶ããŒã ã«èããšãã質å
- ãã®ç ç©¶ã®ç®çã¯äœã§ããïŒ
- ã©ã®ãããªçš®é¡ã®ç ç©¶ã§ããïŒïŒè©Šéšã芳å¯ç ç©¶ãã該åœããã°åææ®µéãåŸææ®µéãïŒ
- èªåã¯äœãããå¿ èŠããããŸããïŒ å蚺ãæé ãæé
- çŸæç¹ã§ããã£ãŠãããªã¹ã¯ã¯äœã§ããïŒ ãããŠããŸã ããã£ãŠããªãããšã¯äœã§ããïŒ
- 代ããã®éžæè¢ã¯äœã§ããïŒ åå ããªããšã©ããªããŸããïŒ
- å¯Ÿç §çŸ€ã¯äœã§ããïŒ æšæºæ²»çãæ¯èŒæ²»çããŸãã¯ãã©ã»ãã§ããïŒ ããã¯ãªãã§ããïŒ
- èªåãè² æ ããè²»çšãšãç ç©¶ãè² æ ããè²»çšã¯äœã§ããïŒïŒäº€éãæ©åšãå蚺ãå«ãïŒ
- éäžã§ããããã©ããªããŸããïŒ
- ã©ã®ãããªããŒã¿ãéãããã誰ãå©çšã§ããŸããïŒïŒå°æ¥ã®ç ç©¶ãããŒã±ãã£ã³ã°ãå«ãïŒ
ãŸãšã
èšåºç ç©¶ã¯ãããããã®æšæºæ²»çãã€ããæ¹æ³ã§ãããã ããåå ã¯ãäžç¢ºå®æ§ããªã¹ã¯ãå®éã®è² æ ã«ã€ããŠççŽã«è©±ãåã£ãããã§ã®ãããèããéžæã§ããã¹ãã§ãã
ç ç©¶ã調ã¹ãããšèªäœã¯ãäœãã«åæããããšã§ã¯ãããŸãããè¯ãç ç©¶ã¯è³ªåãæè¿ããæ±ºããŠæ¥ãããŸããã
åèæç®
- American Academy of OtolaryngologyâHead and Neck Surgery Foundation (AAO-HNSF). Clinical Practice Guideline (Update): Sudden Hearing Loss. å ¬éæ¥: 2019幎8æ1æ¥. https://www.entnet.org/wp-content/uploads/2021/04/sudden_hearing_loss_slideset_.pptx
- U.S. Department of Health and Human Services. 45 CFR 46 â Protection of Human Subjects (Common Rule). eCFRïŒçŸè¡çïŒ. https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46/subpart-A
- International Council for Harmonisation (ICH). E10: Choice of Control Group and Related Issues in Clinical Trials.ïŒã¬ã€ãã©ã€ã³ïŒ https://www.ich.org/page/efficacy-guidelines
- U.S. Food and Drug Administration (FDA). Investigational Device Exemption (IDE)ïŒå»çæ©åšã®èšåºç ç©¶ã®æŠèŠïŒ. https://www.fda.gov/medical-devices/investigational-device-exemption-ide/ide-approval-process
- Nguyen Y, et al. Bilateral gene therapy in children with DFNB9 (OTOF-related) auditory neuropathy. Nature Medicine. 2024.ïŒãªãŒãã³ã¢ã¯ã»ã¹PDFïŒ https://www.nature.com/articles/s41591-024-03088-5.pdf
- ClinicalTrials.gov. Find StudiesïŒç»é²ãµã€ãïŒ. https://clinicaltrials.gov/
- National Institutes of Health (NIH). Clinical Research Trials and YouïŒåå è åãåºç€æ å ±ïŒ. https://www.nih.gov/health-information/nih-clinical-research-trials-you
ç ç©¶ã«é¢å¿ããããªã次ã«ã§ããããš
ãŸãã©ã®ãããªç ç©¶ããããã調ã¹ããã®åŸã§èŽèŠå°éè·ãè³ã®å°éå»ãšéžæè¢ã«ã€ããŠçžè«ããŠã¿ãŸãããã調ã¹ãããšèªäœã¯åå ã®çŽæã§ã¯ãªããæ å ±ãåŸãããã®äžæ©ã§ãã